RBCC Exploring Options and Partners for Alcohol Addiction Treatment Center in Texas

Rainbow Coral Corp. (OTCQB:RBCC) is investigating the feasibility of starting a low-cost alcohol addiction treatment center in Texas, part of the company’s previously announced strategy of creating an inclusive, affordable program to assist people unable to get help via pricier clinics. RBCC is actively seeking interested parties to participate in the project as joint venture partners.

“Texas could be a suitable starting point for what could be a series of progressive, affordable treatment centers,” said RBCC CEO Kimberly Palmer. “We ultimately envision centers throughout the U.S., but Texas holds promise as a potential pilot project. Its population often lacks the financial resources to participate in more traditional programs. Such a population could find a new approach, such as the one we would offer, appealing.”

Anti-alcoholism organizations have estimated alcohol addiction and abuse costs Texans $15 billion annually – a tab activists stress only includes medical and legal costs. Texas also has a higher rate of death from alcohol per 100,000 population than the national average. However, the true overall cost is undoubtedly much higher, as it may be impossible to calculate the social price alcohol abuse and addiction wreaks on individuals, families, employers and society as a whole.

“A center like the one we’re considering could make a dramatic and positive difference in those sad statistics above,” Palmer said.

Through its biotech subsidiary, Rainbow Biosciences, RBCC markets and develops new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (BIIB), Abbott Laboratories (ABT) and Amgen Inc. (AMGN).

For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151223005126/en/